Prostate Cancer Diagnosis Has Not Deterred Larry Hagman From Working | MedIndia - 0 views
-
med india on 31 Oct 11Brave heart Larry Hagman has vowed to keep on working despite battling prostate cancer.
Group items tagged
ACETO completes acquisition of PACK Pharmaceuticals - 1 views
-
Published 01 May 2014 ACETO has announced that its wholly-owned subsidiary, Rising Pharmaceutical, has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100m.
Nutrient Packed Pomegranate | Medindia - 0 views
-
Pomegranate has long been a valuable crop that produces nutritive fruits. The entire tree is of great economic importance. Loaded with vitamins C and B, potassium, folic acid and iron, the pomegranate is in true sense "a superfood". Above all, each edible seed of pomegranate is a source of fiber. With its delicious taste, easy availability, and relatively economic value, it sure is a soothing fruit for the stomach. Various studies also suggest that pomegranate is very rich in antioxidants, almost three times the antioxidants found in green tea or red wine.
Dementia Spending in Britain Tops £34 Billion a Year | MedIndia - 0 views
-
A new study has revealed that Britain spends over £34 billion a year on the care for patients suffering from Alzheimer's disease and dementia.
Novartis launches Lucentis PFS in Germany - 1 views
-
PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.
Beyond Human Limits: How Dr. Somashekhar SP is Pushing the Boundaries of Cancer Treatme... - 0 views
-
Dr. Somashekhar SP is renowned for his vast experience and expert is in advanced integrative medicines, which has helped many cancer patients around the world.
Developing Self Confidence In Children - 1 views
My husband and I were really worried with the indifference that our second child has been showing. We noticed that she did not like to mingle with other kids in the class. Her teacher even told us ...
The Best Ideal Home Fitness Equipment Calgary - 1 views
If you want to really get into shape and tone and build your muscle while cutting fat, then perhaps the best way to do this is using home fitness equipment calgary which has many advantages over go...
Child Therapy Works - 2 views
I have the chance of asking professional help for my kid who has been depressed for the past few weeks. We did not know what the reason was and so we asked help from NLP4Kids a reputed therapy orga...
Effective Stretch Mark Remedy - 1 views
I gave birth six months ago. What bothers me are these stretch marks that are found in my belly. I could not wear my swim wear attire whenever my family would decide to stay at the beach to swim. I...
Epic Sciences partners with LabCorp for circulating tumor cell technology - 0 views
-
Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.
OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views
-
Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors
Immuneering expands relationship with Bristol-Myers Squibb - 0 views
-
Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.
BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views
-
BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.
Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views
-
Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.
Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views
-
Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology
DARPA's vaccine manufacturing challenge - 0 views
-
The prospect of global pandemic is worrying for public health authorities, with the sufficient supply of vaccines a particular concern. In the US, DARPA's Blue Angel project has been working on alternative plant-based vaccine production methods, with impressive results.
Agenus acquires Swiss biopharmaceutical firm 4-Antibody - 0 views
-
US-based developer of new immunotherapeutics, including a portfolio of checkpoint modulators, anti-cancer vaccines and adjuvants, Agenus has completed the acquisition of Switzerland-based biopharmaceutical firm 4-Antibody.
CHA announces new program to accelerate innovation in life sciences and health care - 0 views
-
Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.
Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views
-
PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).